Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Meditech Research was created in January 1999 with the acquisition, by a group of Australian investors, of the majority shareholding in what was previously Hyal Pharmaceutical Australia. Meditech acquired patented technology in relation to the naturally-occurring sugar hyaluronan and, in particular, rights to Solarase, a topical gel which had been developed for the treatment of sunspots.